Conduit Pharmaceuticals (CDT) Competitors $4.72 -1.03 (-17.91%) Closing price 04:00 PM EasternExtended Trading$4.74 +0.02 (+0.32%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDT vs. LPTX, TXMD, XFOR, RLMD, GLYC, BFRG, PMN, CING, ALLR, and GOVXShould you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include Leap Therapeutics (LPTX), TherapeuticsMD (TXMD), X4 Pharmaceuticals (XFOR), Relmada Therapeutics (RLMD), GlycoMimetics (GLYC), Bullfrog AI (BFRG), ProMIS Neurosciences (PMN), Cingulate (CING), Allarity Therapeutics (ALLR), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry. Conduit Pharmaceuticals vs. Leap Therapeutics TherapeuticsMD X4 Pharmaceuticals Relmada Therapeutics GlycoMimetics Bullfrog AI ProMIS Neurosciences Cingulate Allarity Therapeutics GeoVax Labs Leap Therapeutics (NASDAQ:LPTX) and Conduit Pharmaceuticals (NASDAQ:CDT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, community ranking, risk and media sentiment. Do insiders and institutionals have more ownership in LPTX or CDT? 30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. 5.4% of Leap Therapeutics shares are owned by company insiders. Comparatively, 30.9% of Conduit Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor LPTX or CDT? In the previous week, Conduit Pharmaceuticals had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 8 mentions for Conduit Pharmaceuticals and 7 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.01 beat Conduit Pharmaceuticals' score of 0.46 indicating that Leap Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Leap Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Conduit Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer LPTX or CDT? Leap Therapeutics received 293 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Conduit Pharmaceuticals an outperform vote while only 68.37% of users gave Leap Therapeutics an outperform vote. CompanyUnderperformOutperformLeap TherapeuticsOutperform Votes29468.37% Underperform Votes13631.63% Conduit PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Is LPTX or CDT more profitable? Conduit Pharmaceuticals' return on equity of 0.00% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -116.24% -93.18% Conduit Pharmaceuticals N/A N/A -328.67% Which has higher earnings and valuation, LPTX or CDT? Leap Therapeutics is trading at a lower price-to-earnings ratio than Conduit Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$81.41M-$1.70-0.21Conduit PharmaceuticalsN/AN/A-$540K-$35.65-0.13 Do analysts recommend LPTX or CDT? Leap Therapeutics currently has a consensus price target of $4.92, indicating a potential upside of 1,260.45%. Given Leap Therapeutics' higher possible upside, research analysts plainly believe Leap Therapeutics is more favorable than Conduit Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Which has more volatility and risk, LPTX or CDT? Leap Therapeutics has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500. SummaryConduit Pharmaceuticals beats Leap Therapeutics on 9 of the 16 factors compared between the two stocks. Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricConduit PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.52M$6.49B$5.36B$8.39BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-0.138.9426.5919.72Price / SalesN/A251.55391.61116.20Price / CashN/A65.8538.2534.62Price / Book-7.616.466.794.51Net Income-$540,000.00$143.98M$3.23B$248.18M7 Day Performance-21.33%3.16%4.03%1.14%1 Month Performance-42.60%7.60%12.22%15.07%1 Year Performance-99.90%-2.36%16.76%6.59% Conduit Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTConduit Pharmaceuticals0.6641 of 5 stars$4.72-17.9%N/A-99.9%$53.52MN/A-0.133News CoverageEarnings ReportStock SplitGap DownLPTXLeap Therapeutics2.4258 of 5 stars$0.41+3.4%$4.92+1,085.3%-85.2%$17.19MN/A-0.2140TXMDTherapeuticsMD0.9008 of 5 stars$1.48-1.3%N/A-30.4%$17.13M$1.76M0.00420Analyst ForecastXFORX4 Pharmaceuticals4.5838 of 5 stars$2.92flat$72.33+2,377.2%-90.0%$16.90M$31.36M-32.4480RLMDRelmada Therapeutics4.436 of 5 stars$0.51+10.4%$4.25+735.0%-81.6%$16.90MN/A-0.1810Positive NewsInsider TradeGap UpGLYCGlycoMimetics2.1339 of 5 stars$0.26+5.2%N/A-9.4%$16.77M$10,000.00-0.5650Earnings ReportBFRGBullfrog AI1.0176 of 5 stars$1.74-0.6%N/A-37.0%$16.38M$60,000.00-2.054Positive NewsPMNProMIS Neurosciences1.6525 of 5 stars$0.50-2.7%$4.50+800.0%-70.7%$16.34MN/A-5.005Gap UpCINGCingulate2.4156 of 5 stars$3.81-0.3%$25.75+575.9%+358.3%$16.18MN/A-0.4520News CoverageAnalyst ForecastAnalyst RevisionALLRAllarity Therapeutics0.1301 of 5 stars$1.07+2.9%N/A-94.2%$16.14MN/A0.0010GOVXGeoVax Labs2.1745 of 5 stars$1.02+3.6%$11.10+988.2%-36.2%$15.50M$5.59M-0.2810 Related Companies and Tools Related Companies Leap Therapeutics Alternatives TherapeuticsMD Alternatives X4 Pharmaceuticals Alternatives Relmada Therapeutics Alternatives GlycoMimetics Alternatives Bullfrog AI Alternatives ProMIS Neurosciences Alternatives Cingulate Alternatives Allarity Therapeutics Alternatives GeoVax Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDT Stock Free CDT Stock Alerts